A Primer on SBRT for Early-Stage Lung Cancer
Stereotactic body radiotherapy (SBRT), also called stereotactic ablative body radiotherapy (SABR), has become an important treatment option for selected patients with early-stage lung cancer. It delivers a small number of highly precise, biologically potent radiation treatments to a lung tumour while limiting exposure to nearby normal tissues.
For medical physicists, SBRT combines clinical judgment with demanding technical practice. Respiratory motion, small target volumes, steep dose gradients, image guidance, treatment planning, and quality assurance all influence whether the prescribed dose reaches the intended target safely.
The subject fits naturally within the scientific and educational interests represented by the Canadian Organization of Medical Physicists. Delegates reviewing the archived scientific program from the 2014 Annual Scientific Meeting in Banff would recognize many of the same themes: evidence-based practice, technology assessment, accurate measurement, and collaboration between physics and clinical teams.
The Clinical Role Of SBRT
Early-stage non-small cell lung cancer (NSCLC) is generally characterized by a localized tumour without distant metastases or extensive nodal involvement. Lobectomy with systematic evaluation of lymph nodes remains a standard curative treatment for medically fit patients. However, some patients cannot tolerate surgery because of poor pulmonary reserve, advanced age, cardiac disease, or other comorbidities.
SBRT provides a non-invasive alternative for patients who are medically inoperable and may also be considered for carefully selected operable patients. Treatment commonly consists of one to five fractions delivered over several days or a few weeks. The high dose per fraction produces a strong tumour-control effect, but it also requires exceptional confidence in target definition and dose delivery.
This approach differs from conventional fractionated radiotherapy, which typically uses many smaller daily fractions. SBRT reduces treatment time and creates a sharp dose fall-off around the target. That advantage is meaningful in the lung, where the tumour may lie close to the chest wall, ribs, oesophagus, heart, or major airways.
Selecting The Patient And Target
Patient selection begins with reliable staging. Diagnostic imaging commonly includes high-quality computed tomography, positron emission tomography, and, where appropriate, brain imaging. Tissue confirmation is preferred when it can be obtained safely, although an empiric treatment decision may be considered in selected cases when imaging strongly supports malignancy and biopsy risk is substantial.
The treatment team must distinguish a primary lung lesion from infection, inflammation, metastatic disease, or a benign nodule. Tumour size, location, histology, growth pattern, pulmonary function, and proximity to critical organs all influence the risk-benefit assessment. Central and ultra-central tumours demand particular caution because high dose may affect the proximal bronchial tree, pulmonary vessels, oesophagus, or heart.
Target delineation requires more than outlining a visible mass on one static scan. Four-dimensional CT can characterize tumour motion through the respiratory cycle. The gross tumour volume is expanded according to the motion-management strategy and setup uncertainty to create an internal target volume or planning target volume. Each margin should be justified rather than applied automatically.
Simulation And Treatment Planning
Simulation should reproduce the treatment position and provide dependable information about respiratory motion. Patients are often immobilized supine with customized supports, although comfort and reproducibility are equally important. Intravenous contrast may improve visualization of vessels and mediastinal structures, while image registration with diagnostic PET or MRI can assist interpretation.
Motion management may involve abdominal compression, breath-hold, respiratory gating, tumour tracking, or an internal target volume approach. No single method is universally best. The choice depends on tumour motion, equipment, patient cooperation, treatment time, and the ability of the clinical team to verify the selected strategy.
Treatment planning typically uses conformal three-dimensional techniques, intensity-modulated radiotherapy, or volumetric modulated arc therapy. The plan should provide adequate target coverage and conformity while meeting dose constraints for organs at risk. Small changes in contouring or beam arrangement can produce substantial changes in dose to nearby structures because SBRT uses steep gradients.
| Planning element | Why it matters | Common verification focus |
|---|---|---|
| Target motion | Lung tumours can shift during breathing | Four-dimensional CT and motion assessment |
| Dose conformity | High dose must be concentrated around the lesion | Isodose distribution and conformity metrics |
| Organ-at-risk limits | Ribs, chest wall, airways, heart, and oesophagus may be close | Review of cumulative dose-volume parameters |
| Setup accuracy | Small geometric errors can affect a small target | Image guidance and residual displacement |
| Calculation quality | Heterogeneous lung tissue challenges algorithms | Independent checks and commissioning data |
Dose calculation algorithms should account accurately for tissue heterogeneity and lateral electronic disequilibrium, especially when small fields pass through low-density lung. The medical physicist should understand the limitations of the planning system, the detector data used for commissioning, and the impact of dose grid size on reported target and organ doses.
Delivery, Image Guidance, And Quality Assurance
Image-guided radiotherapy is central to SBRT. Cone-beam CT, stereoscopic imaging, or other onboard imaging methods help confirm the tumour region and the relationship between the target and nearby anatomy immediately before treatment. Fiducial markers are sometimes used, although they are not necessary for every peripheral lung lesion.
Verification does not end after initial alignment. Intrafraction motion can occur as the patient breathes, relaxes, or shifts on the treatment couch. Depending on the technique, the team may use repeated imaging, gating, breath-hold monitoring, or treatment interruption thresholds. The selected workflow should be documented clearly and tested under realistic clinical conditions.
Quality assurance must cover the entire chain from simulation to delivery. Machine output, beam modeling, multileaf collimator performance, imaging systems, couch coordinates, immobilization, and end-to-end geometric accuracy all matter. Patient-specific checks may include phantom measurements, independent dose calculations, or secondary verification of monitor units and plan parameters.
The small fields and high dose per fraction make measurement particularly demanding. Detector size, volume averaging, angular response, output factors, and detector positioning can influence results. A robust SBRT program therefore relies on validated protocols, staff training, peer review, and incident-learning processes rather than a single pass-fail measurement.
Expected Outcomes And Possible Toxicities
For medically inoperable patients with stage I NSCLC, SBRT has produced high rates of local control in many prospective and retrospective studies. Outcomes vary with tumour size, location, histology, staging quality, patient health, and follow-up duration. Local control is only one measure of success; overall survival may remain limited by chronic lung disease, cardiovascular illness, or second primary cancers.
Radiation pneumonitis is a recognized toxicity and may present with cough, dyspnoea, fever, or radiographic lung changes. Chest-wall pain and rib fracture are more likely when a peripheral tumour abuts the pleura or ribs. Other complications can include oesophageal injury, brachial plexopathy, airway damage, haemorrhage, or cardiac effects, with risk strongly influenced by tumour location and dose distribution.
Follow-up imaging can be difficult to interpret. Fibrotic changes after SBRT may resemble recurrent tumour, and the appearance can evolve for months or years. Clinical assessment, serial imaging, PET when appropriate, and multidisciplinary review help distinguish treatment effect from recurrence. Clear communication between radiation oncology, radiology, pulmonology, surgery, and physics supports safer decision-making.
Building A Reliable SBRT Program
A successful service is built around shared responsibility. Radiation oncologists define the clinical intent and contours, radiologists support image interpretation, radiation therapists manage positioning and imaging workflows, and medical physicists validate the technology and measurement systems. Regular case review helps identify borderline anatomy and refine institutional practice.
Documentation is especially important for high-dose hypofractionated treatments. The record should identify the prescription, fractionation, motion strategy, immobilization method, image-guidance protocol, target and organ-at-risk constraints, plan review, and treatment-delivery checks. Consistent terminology reduces ambiguity during planning and treatment.
Professional meetings also provide a setting for discussing how technical standards develop across institutions. Historical conference materials, including the discussion of future conference locations, illustrate the broader organizational work that supports scientific exchange, continuing education, and national collaboration in medical physics.
Practical Priorities For Clinical Teams
- Establish written selection criteria for peripheral, central, and ultra-central lung lesions.
- Validate four-dimensional imaging, motion assessment, and image-guidance workflows before clinical use.
- Commission dose calculation algorithms and small-field measurements with appropriate phantoms and detectors.
- Use prospective peer review for target contours, dose constraints, and treatment plans.
- Track outcomes, toxicity, near misses, and technical deviations through a structured quality-improvement process.
SBRT is powerful because it concentrates radiation where it is needed, but precision is a clinical system rather than a single device feature. Careful staging, reproducible simulation, defensible planning, accurate delivery, and long-term follow-up must work together. Delegates and professionals using this archived conference resource can review registration information alongside the scientific material, then apply the same habits of preparation, verification, and collaboration to contemporary stereotactic practice.